Cover image for The biotech investor : how to profit from the coming boom in biotechnology
The biotech investor : how to profit from the coming boom in biotechnology
Abate, Tom.
Personal Author:
First edition.
Publication Information:
New York : Times Books, [2003]

Physical Description:
xiii, 289 pages : illustrations ; 25 cm
General Note:
Includes index.
Electronic Access:
Publisher description
Format :


Call Number
Material Type
Home Location
Item Holds
HD9999.B442 A2 2003 Adult Non-Fiction Central Closed Stacks

On Order



A sophisticated investor's practical tool kit for
analyzing the science, business, opportunities, and risks in the century's most promising industry
The world is entering a biotechnology boom-but only informed investors will prosper in the incredibly complex biotech business. Separating the bioengineered wheat from the chaff, San Francisco Chronicle science and technology columnist Tom Abate, one of the top objective authorities on biotech, gives investors the analytical foundation to understand the science, finances, time horizon, and technological and commercial potential of this burgeoning industry.
In "The Biotech Investor," Abate provides sophisticated business analysis, guidelines for assessing company leadership, easy-to-digest reports from the labs, and indispensable investor tools and metrics. He explains how breaking news, medical conferences, U.S. Food and Drug Administration approvals, and the patent process affect investing strategies. Finally, he looks beyond medicine to review the financial opportunities presented by biotechnology advances in everything from agriculture to jean manufacturing, and shows investors how to identify "coattail" industries such as instrumentation and software development that will benefit from biotech successes.
The Biotech Investor is the comprehensive, expert source for successful and intelligent investing in one of the twenty-first century's most promising industries.

Author Notes

Tom Abate is an award-winning technology and health care reporter for the San Francisco Chronicle. He lives in San Leandro, California

Reviews 3

Booklist Review

For investors having a hard time grasping concepts in computer technology, the biotechnology business is even more mystifying. With futuristic names like Genentech, Protein Design Labs, and Human Genome Sciences, an excruciatingly long product development cycle, and very light coverage by analysts, this sector is one of the most difficult for the stock-buying public to understand. However, despite a few public mishaps of their own, biotech stocks as a whole have held up better through the downturn than the overall tech sector. Abate is one of the few writers who closely watch this area, and writes the "BioScope" column for the San Francisco Chronicle. He admits that biotech stocks are among some of the most difficult to play, and warns against jumping into any of the speculative startups in this field. Instead he recommends most investors stick to the handful of companies that have already shown a profit. With plenty of charts and detailed coverage of many individual companies, this would be an excellent source to begin research on this area of cutting-edge medicine. --David Siegfried

Publisher's Weekly Review

With the population aging and eager for medical innovations, the market for biotechnology is vast. But for investors looking at biotech firms, it can be a minefield: before a company's brilliant ideas pan out as profitable products, they must go through years of costly research and development, clear government regulatory hurdles and sometimes, as with genetically modified foods, weather political controversy. This informative and well-written primer will help individual investors navigate the treacherous terrain of biotech stocks. Abate, a biotechnology and health care reporter for the San Francisco Chronicle, provides an overview of each sector of the biotechnology industry and the leading companies in it, tells where to find up-to-date information on the scientific and medical developments that drive the market, and explains how to evaluate the financial prospects of the often shaky start-ups that crowd the field. His advice is appropriately cautious; he suggests putting no more than 20% of a portfolio in biotechnology, and waiting until a company is in hailing distance of profitability before investing. While the book is pitched at the non-professional, Abate makes it clear that these speculative, volatile and often over-sold stocks demand more effort-he recommends reading scientific journals, attending conferences and perusing the patent literature -than a complacent mutual-fund investor is used to. But for those willing to brave the new world of biotechnology, this is a good place to start. 20 charts and graphs. (Feb.) (c) Copyright PWxyz, LLC. All rights reserved

Library Journal Review

Most investors are advised to buy and hold, but investing in biotechnology stock requires a different strategy. Because biotech medicines are experimental in nature and require strict regulatory review from the U.S. Food and Drug Administration, such investments usually are high risk, so why would anyone want to buy stocks in this sector? Abate, a biotechnology, technology, and healthcare reporter who writes a weekly "BioScope" column for the San Francisco Chronicle, here argues that the biotechnology sector has become especially interesting to investors owing to the maturation of biotech science and the aging of the population: "Companies in this industry are attacking the root causes of cancer, heart attack, Parkinson's disease and other modern scourges." Abate is forthright when discussing risk in this field and gives the reader the information needed to identify, evaluate, and invest in biotech companies. He discusses how to track stocks using the two biotech indexes on the stock exchange and indicates specific ways to search the Internet when investigating the biotechnology field. Like Jim McCamant's Biotech Investing: Every Investor's Guide, this book argues that now is the time to invest in biotech companies, but readers should remember that this is advisable only for high-risk investors. Such investors will find this book clear and understandable. Recommended for public libraries.-Bellinda Wise, Nassau Community Coll. Lib., Garden City, NY (c) Copyright 2010. Library Journals LLC, a wholly owned subsidiary of Media Source, Inc. No redistribution permitted.

Table of Contents

Preface: The Biotech Wavep. vii
1 The Foundations of Biotech Investingp. 1
2 The Age Wave and the Market for New Medicinesp. 23
3 The Genomics Wave: The Drug Discovery Marathonp. 47
4 The Proteomics Wave: Proteins and The Next Medicinesp. 73
5 Picks and Shovels: The Biotech Toolmakersp. 97
6 Green Genes: Agricultural Biotechnologyp. 121
7 The New Factories: Industrial Biotechnologyp. 147
8 Brave New Worlds: Stem Cells, Clones, and Other Frontiersp. 169
9 The Biotech Clusters: Follow the Leadersp. 197
10 The Investment Frontierp. 219
Appendix I Public Biotechnology Firmsp. 243
Appendix II Biotechnology Firms by Nichep. 261
Appendix III Research Resourcesp. 271
Acknowledgmentsp. 275
Indexp. 279